Evidence map›Paper›PMID 26491148›Full record

ArticleJournal of virology2016

Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection.

Shilpi Verma, Daniela Weiskopf, Ankan Gupta, Bryan McDonald, Bjoern Peters, Alessandro Sette, Chris A Benedict

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Cytotoxic CD4Frontiers in immunology · 2023
    Review
  14. Review
  15. Article
  16. CD4Journal of virology · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shilpi VermaDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Daniela WeiskopfDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Ankan GuptaDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Bryan McDonaldDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Chris A BenedictDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA benedict@lji.org.
La Jolla Institute for Immunology · US

Funding

The role of TRAIL in immune control of cytomegalovirusR01AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2013 to 2023
$4.6M
The role of TRAIL in immune control of cytomegalovirusR56AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2012 to 2012
$435k
NIAID NIH HHS AI101423NIAID NIH HHS R01 AI101423NIAID NIH HHS R56 AI101423PHS HHS HHSN27220140045C
6 · The paper itself

Abstract

unlabelledCD4 T cells provide protection against cytomegalovirus (CMV) and other persistent viruses, and the ability to quantify and characterize epitope-specific responses is essential to gain a more precise understanding of their effector roles in this regard. Here, we report the first two I-A(d)-restricted CD4 T cell responses specific for mouse CMV (MCMV) epitopes and use a major histocompatibility complex class II (MHC-II) tetramer to characterize their phenotypes and functions. We demonstrate that MCMV-specific CD4 T cells can express high levels of granzyme B and kill target cells in an epitope- and organ-specific manner. In addition, CD4 T cell epitope vaccination of immunocompetent mice reduced MCMV replication in the same organs where CD4 cytotoxic T lymphocyte (CTL) activity was observed. Together, our studies show that MCMV epitope-specific CD4 T cells have the potential to mediate antiviral defense by multiple effector mechanisms in vivo. IMPORTANCE: CD4 T cells mediate immune protection by using their T cell receptors to recognize specific portions of viral proteins, called epitopes, that are presented by major histocompatibility complex class II (MHC-II) molecules on the surfaces of professional antigen-presenting cells (APCs). In this study, we discovered the first two epitopes derived from mouse cytomegalovirus (MCMV) that are recognized by CD4 T cells in BALB/c mice, a mouse strain commonly used to study the pathogenesis of this virus infection. Here, we report the sequences of these epitopes, characterize the CD4 T cells that recognize them to fight off MCMV infection, and show that we can use the epitopes to vaccinate mice and protect against MCMV.

Indexed as

Cytotoxicity, ImmunologicAnimalsCD4-Positive T-LymphocytesCell SurvivalCytomegalovirus VaccinesGranzymesMice, Inbred BALB CMuromegalovirusTombusviridaeCytomegalovirus VaccinesGranzymes

Identifiers

PMID26491148
PMCPMC4702662
OpenAlexW2282684999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.